Gil Roth01.17.12
Evotec AG and Harvard University have launched their second strategic alliance. This new pact, known as "CureNephron," will include Brigham and Women's Hospital and is aimed at discovering and developing new biomarkers and treatments in the field of kidney disease. The first successful collaboration "CureBeta" was established in March 2011 to develop new diabetes therapies targeting beta cell regeneration.
The groups will bring together extensive expertise in kidney biology, physiology and disease, and a unique set of tools to identify, validate and develop candidate targets and biomarkers. The alliance will pursue systematic and unbiased approaches towards the identification of kidney disease relevant mechanisms, with particular interest in mechanisms with disease-modifying potential. The program is designed to deliver and exploit novel therapeutic targets, as well as biomarkers that allow more accurate diagnosis, monitoring and treatment of chronic and acute kidney disease.
Dr. Cord Dohrmann, chief scientific officer of Evotec, remarked, "We are extremely proud to work with Dr. Andy McMahon and Dr. Ben Humphreys, who are highly accomplished scientists and clinicians in this exciting field. Together with Evotec scientists, they will be part of a uniquely cross-functional team covering kidney biology, physiology, and disease as well as leading drug discovery expertise. Our combined efforts will lead to new insights into kidney disease biology and fuel a pipeline of commercially exciting drug candidates in acute and chronic kidney disease."
Financial terms of the alliance were not disclosed.
The groups will bring together extensive expertise in kidney biology, physiology and disease, and a unique set of tools to identify, validate and develop candidate targets and biomarkers. The alliance will pursue systematic and unbiased approaches towards the identification of kidney disease relevant mechanisms, with particular interest in mechanisms with disease-modifying potential. The program is designed to deliver and exploit novel therapeutic targets, as well as biomarkers that allow more accurate diagnosis, monitoring and treatment of chronic and acute kidney disease.
Dr. Cord Dohrmann, chief scientific officer of Evotec, remarked, "We are extremely proud to work with Dr. Andy McMahon and Dr. Ben Humphreys, who are highly accomplished scientists and clinicians in this exciting field. Together with Evotec scientists, they will be part of a uniquely cross-functional team covering kidney biology, physiology, and disease as well as leading drug discovery expertise. Our combined efforts will lead to new insights into kidney disease biology and fuel a pipeline of commercially exciting drug candidates in acute and chronic kidney disease."
Financial terms of the alliance were not disclosed.